Arrowhead Pharmaceuticals, Inc. today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement ...

PAR Technology , a global foodservice technology company, today announces that Condado Tacos, the rapidly growing restaurant brand celebrated for its custom tacos and bold flavors, has selected PAR® ...

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

We’ll also explore the company’s innovative approach to treating cancer, particularly those driven by KRAS mutations, and why Prof. Peled’s addition could be a game-changer. The recent appointment of ...

The agency is due to make a determination on the shortage status of Zepbound by Dec. 19. But another delay could be possible ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

Researchers at the University of Ottawa have figured out how to use mRNA and RNAI-based treatments to treat complex illnesses ...

Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded ...

The oligonucleotides market has gained significant traction in recent years due to its critical role in molecular biology, genetics, and therapeutics. Oligonucleotides, short DNA or RNA molecules, are ...

Acute Intermittent Porphyria (AIP) is a rare genetic disorder that has gained increasing attention in recent years. It stems ...

Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to improve ...

Researchers have recently revealed new insights into how brittle stars can reversibly adjust the pliability of their tissues.